CNS Therapeutics - A World Market Review

1.METHODOLOGY
Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level
2.GLOBAL MARKET OVERVIEW AND OUTLOOK
Factors Influencing Demand
The ‘Age Factor’
Role of Diagnostic Techniques
Increasing Disease Awareness
Emergent Technologies
Reimbursement Policies
Outlook
Market Trends and Issues
Booming Therapeutic Opportunities for Neuro-Degenerative Disorders
Spur in CNS Drug Delivery Technologies
Migraine Market Offers Growth Opportunities to Prophylaxis Products
Demand for Therapeutic Peptides Spurred by Dearth of Effective Therapies
Anti-Depressants
Major Trends in the Depression Market
SSRIs are the Preferred Choice Despite Side Effects
Attention Deficit Hyperactivity Disorder (ADHD)
Major Trends in the ADHD Market
Anti-Psychotics Market
Restrictions on Promotion Hamper Market Prospects
Insomnia
Anti-Insomnia Drugs from Corporate Giants Flood the Sleep Market
Neuropathic Pain
Patent Expiry of Leading CNS Drugs: 2005-2017
3.PRODUCT FACTS
CNS Disorders
A. Anti-Alzheimer's Drugs
B. Anti-Parkinson's Drugs
C. Anti-Epilepsy Drugs
D. Pain Management Drugs
E. Anti-Psychotics Drugs
(i)Bipolar disorder
(ii)Schizophrenia
F. Anti-Depressants Drugs
G. Others
(i)Attention Deficit Hyperactivity Disorder
(ii)Multiple Sclerosis
(iii)Insomnia
(iv) Restless Legs Syndrome
(v) Anxiety
4.CORPORATE DEVELOPMENTS
P1vital Creates Global Consortium to Develop CNS Experimental Medicine
Neurobiological Tech Teams Up with Buck Institute
ExonHit Therapeutics and Allergan Ink Contract to Develop CNS Agents
NeuroSearch Commences Clinical Phase I study with NSD-788 in France
Abilify® Meets CHMP Standards
UCB Receives Recommendation for Approval for Neupro®
Schering-Plough Acquires Organon
UCB Launches Neupro® in the US
GlaxoSmithKline Forms Alliance with Targacept
GSK Teams-Up with Sepracor for Commercializing Lunivia®
US FDA Rebut NDA for bifeprunox
Medtronic and Alnylam Extend their Drug- Device Collaboration
Neuren Takes Over Hamilton
Roche Forms Partnership with Synosis Therapeutics to Evaluate Five CNS Compounds
NeuroSearch Starts Clinical Phase I Study with ACR343 in Sweden
Lundbeck to Promote Circadin® in Europe
Sepracor Inks Partnership with Eisai to Develop and Market
Lunesta® in Japan
5.MAJOR PLAYERS
Abbott Laboratories (USA)
Alkermes, Inc. (USA)
AstraZeneca Plc (UK)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb (USA)
Cephalon, Inc. (USA)
Dainippon Sumitomo Pharma Co., Ltd. (Japan)
Elan Corporation Plc (Ireland)
Eli Lilly and Co. (USA)
Fabre-Kramer Pharmaceuticals, Inc. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Forest Laboratories, Inc. (USA)
GlaxoSmithKline (UK)
H. Lundbeck A/S (Denmark)
Johnson & Johnson (USA)
Janssen Pharmaceutica N.V. (Belgium)
Janssen-Cilag (Switzerland)
Merck & Co., Inc. (USA)
Neurocrine Biosciences, Inc. (USA)
Novartis AG (Switzerland)
Sandoz International GmbH (Germany)
Organon N.V. (The Netherlands)
Ortho-McNeil Neurologics, Inc. (USA)
Otsuka Pharmaceutical Co., Ltd. (Japan)
Pfizer, Inc. (USA)
Sanofi-Aventis (France)
Schwarz Pharma AG (Germany)
Sepracor, Inc. (USA)
Shire Plc (UK)
Solvay Pharmaceuticals S.A. (Belgium)
Takeda Pharmaceutical Co., Ltd. (Japan)
Teva Pharmaceutical Industries Ltd. (Israel)
UCB S.A. (Belgium)
Wyeth (USA)
6.GLOBAL MARKET ANALYTICS
7.THE UNITED STATES
Cost Implications of CNS Disorders
Alzheimer's Market
Anti-Alzheimer’s Drugs Approved for Use in the Past
Cost of Care to AD Patient
Clinical Pipeline
Anti-Psychotics
Growth Dampeners
Clinical Pipeline
Antidepressants
Antidepressants to Feature Black-Box Warnings
Antidepressant Consumption Falls Among Children and Adolescents
Multiple Sclerosis
Insomnia Market
Rising Consumption of ADHD Drugs Combat Safety Concerns
Unmet Medical Needs in Neuropathic Pain Offer Growth Prospects
CNS Tuberculosis Raises its Ugly Head
8.CANADA
Facts & Figures
9.EUROPE
a.France
b.Germany
c.Italy
d.The United Kingdom
e.Spain
f.Rest of Europe
10.ASIA-PACIFIC
An Overview of the Japanese Market
Pain Management Market

11.LATIN AMERICA
12.REST OF WORLD
Exhibits
Table 1: Sales of Leading ADHD Drug Brands in the World – 2005 (In US$M)
Table 2: Sales of Leading Atypical Anti- Psychotic Drug Brands in the World – 2005 (In US$ Million)
Table 3: Percentage Breakdown of Leading Anti-Psychotics Brands Value Sales in the World –
Table 4: Percentage Breakdown of Leading Anti-Parkinson’s Disease Brands Value Sales in the World –
Table 5: Sales of Leading Epilepsy Drug Brands in the World – 2005 (In US$ Million)
Table 6: Global CNS Therapeutics Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 7: Percentage Breakdown of Global CNS Therapeutics Market by Region for the Years 2008 & 2009
Table 8: Global Anti-Alzheimer's Drugs Market by Region for the Period 2007- 2015 (Sales in US$ Million)
Table 9: Percentage Breakdown of Global Anti-Alzheimer's Drugs Market by Region for the Years 2008 & 2009
Table 10: Global Anti-Parkinson's Drugs Market by Region for the Period 2007- 2015 (Sales in US$ Million)
Table 11: Percentage Breakdown of Global Anti-Parkinson's Drugs Market by Region for the Years 2008 & 2009
Table 12: Global Anti-Epilepsy Drugs Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 13: Percentage Breakdown of Global Anti-Epilepsy Drugs Market by Region for the Years 2008 & 2009
Table 14: Global Pain Management Drugs Market by Region for the Period 2007- 2015 (Sales in US$ Million)
Table 15: Percentage Breakdown of Global Pain Management Drugs Market by Region for the Years 2008 & 2009
Table 16: Global Anti-Psychotics Drugs Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 17: Percentage Breakdown of Global Anti-Psychotics Drugs Market by Region for the Years 2008 & 2009
Table 18: Global Anti-Depressants Drugs Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 19: Percentage Breakdown of Global Anti-Depressants Drugs Market by Region for the Years 2008 & 2009
Table 20: Global Other CNS Drugs Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 21: Percentage Breakdown of Global Other CNS Drugs Market by Region for the Years 2008 & 2009
Table 22: Percentage Breakdown of Leading Alzheimer Brands Value Sales in the US –
Table 23: Percentage Breakdown of Leading Anti-Psychotics Brands Value Sales in the US –
Table 24: Percentage Breakdown of Leading Atypical Anti-Psychotic Brands Value Sales in the US –
Table 25: Sales of Leading Antidepressant Drug Brands in the US – 2006 (In US$M)
Table 26: Percentage Breakdown of Leading Anti-Multiple Sclerosis Drug Brands Value Sales in the US –
Table 27: Percentage Breakdown of Leading ADHD Brands Sales in the US –
Table 28: Percentage Breakdown of Leading Pain Management Manufacturers Value Sales in the US –
Table 29: CNS Therapeutics Market by Segment in the US: 2007-2015 (Sales in US$ Million)
Table 30: Percentage Breakdown of CNS Therapeutics Market by Segment in the US for the Years 2008 & 2009
Table 31: CNS Therapeutics Market by Segment in Canada: 2007-2015 (Sales in US$ Million)
Table 32: Percentage Breakdown of CNS Therapeutics Market by Segment in Canada for the Years 2008 & 2009
Table 33: Percentage Breakdown of Anti-Psychotics Market Revenues by Product Class in Europe –
Table 34: Percentage Breakdown of Leading Atypical Anti-Psychotics Brand Value Sales in Europe –
Table 35: Percentage Breakdown of Leading Anti-Depressant Brands Value Sales in Europe –
Table 36: Percentage Breakdown of Antidepressants Market Revenues by Segment in Europe –
Table 37: CNS Therapeutics Market by Region in Europe: 2007-2015 (Sales in US$ Million)
Table 38: Percentage Breakdown of CNS Therapeutics Market by Region in Europe for the Years 2008 & 2009
Table 39: CNS Therapeutics Market by Segment in Europe: 2007-2015 (Sales in US$ Million)
Table 40: Percentage Breakdown of CNS Therapeutics Market by Segment in Europe for the Years 2008 & 2009
Table 41: CNS Therapeutics Market by Segment in France: 2007-2015 (Sales in US$ Million)
Table 42: Percentage Breakdown of CNS Therapeutics Market by Segment in France for the Years 2008 & 2009
Table 43: CNS Therapeutics Market by Segment in Germany: 2007-2015 (Sales in US$ Million)
Table 44: Percentage Breakdown of CNS Therapeutics Market by Segment in Germany for the Years 2008 & 2009
Table 45: CNS Therapeutics Market by Segment in Italy: 2007-2015 (Sales in US$ Million)
Table 46: Percentage Breakdown of CNS Therapeutics Market by Segment in Italy for the Years 2008 & 2009
Table 47: CNS Therapeutics Market by Segment in the UK: 2007-2015 (Sales in US$ Million)
Table 48: Percentage Breakdown of CNS Therapeutics Market by Segment in the UK for the Years 2008 & 2009
Table 49: CNS Therapeutics Market by Segment in Spain: 2007-2015 (Sales in US$ Million)
Table 50: Percentage Breakdown of CNS Therapeutics Market by Segment in Spain for the Years 2008 & 2009
Table 51: CNS Therapeutics Market by Segment in Rest of Europe: 2007- 2015 (Sales in US$ Million)
Table 52: Percentage Breakdown of CNS Therapeutics Market by Segment in Rest of Europe for the Years 2008 & 2009
Table 53: CNS Therapeutics Market by Segment in Asia-Pacific: 2007-2015 (Sales in US$ Million)

Table 54: Percentage Breakdown of CNS Therapeutics Market by Segment in Asia-Pacific for the Years 2008 & 2009
Table 55: CNS Therapeutics Market by Segment in Latin America: 2007-2015 (Sales in US$ Million)
Table 56: Percentage Breakdown of CNS Therapeutics Market by Segment in Latin America for the Years 2008 & 2009
Table 57: CNS Therapeutics Market by Segment in Rest of World: 2007- 2015 (Sales in US$ Million)
Table 58: Percentage Breakdown of CNS Therapeutics Market by Segment in Rest of World for the Years 2008 & 2009
Companies Profiled